La Trobe University

Exosomes are emerging as key tools in personalized and regenerative medicine, offering precise, targeted therapy with low immune risk. Their potential spans cancer, chronic disease, and regenerative applications, driven by biopharma's investment in biologics and gene therapies. Stem cell-derived exosomes further enhance tissue repair and immune modulation, positioning exosomes as transformative in next-gen therapeutics. LAS VEGAS, Nov. 4, 2024 /PRNewswire/ -- DelveInsight's ' Exosomes Pipeline Insight 2024 ' report provides comprehensive global coverage of available, marketed, and pipeline exosomes-based therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the exosomes-based therapies pipeline domain. Key Takeaways from the Exosomes-based Therapies Pipeline Report DelveInsight's exosomes pipeline report depicts a robust space with 70+ active players working to develop 80+ pipeline therapies for various indications. Key exosomes-based therapies companies such as Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, Exostemtech, Brexogen, OmniSpirant, ShiftBio Inc., and others are evaluating new exosomes-based therapies to improve the treatment landscape. Promising exosomes-based therapies in the pipeline in various stages of development include CAP-1002, Progenza, AGLE 102, ExoCoVac, COYA 201, EV-101, StemXO Endosome Therapy, BRE AD01, ILB 202, Zofin, exoSTING, ExoFlo, CARTISOME, BRE MI01, OS006, SBI-407, and others. In July 2024, Aruna Bio announced the issuance of a US Patent for the composition of matter for neural exosomes used to deliver therapeutics to the brain. The company is on a rack to initiate Phase Ib/IIa clinical trial of AB126 in acute ischemic stroke in the second half of 2024. In July 2024, ILIAS Biologics announced that it had received the final clinical study report (CSR) for ILB-202, a Phase I clinical trial completed in Australia in November last year. In April 2024, Biological Dynamics joined the growing list of customers adopting the ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform. In April 2024, EXO Biologics secures up to EUR 16 million in Series A funding for exosome therapeutic development and clinical supply. In April 2024, ExoXpert entered a strategic partnership with Neucore Bio to leverage ExoXpert's platform for the evaluation of advanced exosome loading. In April 2024, INOVIQ and Promega signed a global supply and distribution agreement for EXO-NET. Last year's company entered into a Co-Marketing agreement. In March 2024, VivaZome Therapeutics and La Trobe University collaborated to explore the therapeutic potential of extracellular vesicles in models of stroke in the laboratory of Professor Chris Sobey. In January 2024, Aegle Therapeutics announced positive 12-week data for the first patient enrolled in Phase I/IIa clinical trial of AGLE-102 for the treatment of severe second-degree burns. Request a sample and discover the recent advances in exosomes-based therapies @ Exosomes Pipeline Outlook The exosomes-based therapies pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage exosomes-based therapies, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the exosomes-based therapies pipeline landscape. Exosomes Overview Exosomes are small extracellular vesicles, typically ranging from 30 to 150 nanometers in diameter, that are secreted by various cell types. They play a crucial role in intercellular communication by facilitating the transfer of proteins, lipids, and RNA between cells. This process can influence various physiological and pathological conditions, including immune responses, cancer progression, and neurodegenerative diseases. By carrying bioactive molecules, exosomes can modulate the behavior of recipient cells, contributing to processes such as tissue repair, immune regulation, and the spread of cancer cells. Their ability to transport molecular cargo makes them a subject of extensive research, particularly in the context of disease mechanisms and therapeutic applications. In recent years, exosomes have garnered significant interest in the field of biomedicine as potential biomarkers for disease diagnosis and as vehicles for targeted drug delivery. Researchers are exploring their use in therapeutic strategies, such as the delivery of RNA-based therapies and proteins, due to their natural ability to evade the immune system and penetrate cellular membranes. Additionally, exosomes derived from stem cells or engineered for specific therapeutic purposes hold promise for regenerative medicine, offering a novel approach to enhance tissue regeneration and repair. The ongoing investigation into the biology of exosomes continues to reveal their multifaceted roles in health and disease, paving the way for innovative applications in diagnostics and therapeutics. Find out more about exosomes-based therapies @ Exosomes-based Therapies in Development A snapshot of the Exosomes-based Therapies Pipeline Drugs mentioned in the report: Learn more about the emerging Exosomes-based therapies @ Exosomes-based Therapies Clinical Trials Exosomes-based Therapies Therapeutics Assessment The exosome-based therapies pipeline report proffers an integral view of the emerging exosome-based therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Exosomes-based Therapies Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Cell replacements, Inflammation mediator modulators, Collagen type VII replacements, Immunosuppressants, NF-kappa B inhibitor Key Exosomes-based Therapies Companies: Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, Exostemtech, Brexogen, OmniSpirant, ShiftBio Inc., and others. Key Exosomes-based Therapies in Pipeline: CAP-1002, Progenza, AGLE 102, ExoCoVac, COYA 201, EV-101, StemXO Endosome Therapy, BRE AD01, ILB 202, Zofin, exoSTING, ExoFlo, CARTISOME, BRE MI01, OS006, SBI-407, and others. Dive deep into rich insights for exosomes-based therapies assessment, visit @ Exosomes-based Therapies Therapeutics Assessment Table of Contents For further information on the exosomes-based therapies pipeline therapeutics, reach out @ Exosomes-based Therapies Pipeline Landscape Related Reports Exosome Therapies Market Exosome Therapies Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key exosome therapies companies, including Direct Biologics, Capricor Therapeutics, Aegle Therapeutics, Vitti Labs, Rion, Aruna Bio, EXO Biologics, EV Therapeutics, ReNeuron, Coya Therapeutics, Evox Therapeutics , among others. Duchenne Muscular Dystrophy Market Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DMD companies, including FibroGen, Santhera Pharmaceutical, Italfarmaco, ReveraGen BioPharma, Cumberland Pharmaceuticals, Sarepta Therapeutics, Antisense Therapeutics, Capricor Therapeutics , among others. Duchenne Muscular Dystrophy Pipeline Duchenne Muscular Dystrophy Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Duchenne muscular dystrophy companies, including Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Pfizer, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, Ultragenyx Pharmaceutical, Dyne Therapeutics, Entrada Therapeutics, AAVogen, PepGen, Antisense Therapeutics, BioMarin Pharmaceutical, Avidity Biosciences, Sarepta Therapeutics, Dyne Therapeutics, Solid Biosciences Inc, Regenxbio, Stealth BioTherapeutics, among others. Atopic Dermatitis Market Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key atopic dermatitis companies, including Arcutis Biotherapeutics, Amgen, Kyowa Kirin, Dermavant Sciences, Cara Therapeutics, Pfizer, Arena Pharmaceuticals, BioMimetix, Eli Lilly and Company, Aldeyra Therapeutics, Inc., Hangzhou Yirui Pharmaceutical Technology Co., Ltd, LEO Pharma, Corvus Pharmaceuticals, Inc., Brexogen Inc., Sanofi, Shaperon, UCB Pharma, Q32 Bio Inc., Akeso, Apogee Therapeutics, Inc., Allakos Inc., Biosion, Inc. , among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Radiology genAI unveiled Harrison.ai has recently introduced a radiology-specific vision language model. Called Harrison.rad.1, the dialogue-based model can perform open-ended chat related to X-ray images. It can detect and localise radiological findings and generate reports, all with an emphasis on clinical safety and accuracy. Unlike existing generative AI models trained on general and open-source data, Harrison.ai's model has been trained on a set of real-world, diverse, and proprietary data that is annotated at scale by a team of medical specialists. The company further claims its genAI model outperformed major LLMs, such as OpenAI's GPT-4o and Microsoft LLaVA-Med, in the competitive Royal College of Radiologists' 2B Rapids examination, scoring an average of 50.88 out of 60 – on par with experienced radiologists. Additionally, Harrison.rad.1 showed 82% accuracy in the VQA-Rad benchmark dataset of clinical X-ray questions and answers and 73% accuracy in Harrison.ai's in-house open-source RadBench dataset. See-Mode bags 510(k) for thyroid ultrasound analysis AI Victoria-based See-Mode Technologies has obtained the first 510(k) clearance from the United States Food and Drug Administration for an AI-powered solution to detect and diagnose thyroid issues in ultrasound scans. Its thyroid ultrasound analysis software detects single or multiple nodules and automatically classifies each based on the American College of Radiology’s TI-RADS rating systems. It also automatically generates a complete worksheet, which radiologists can immediately review and amend, and provides preliminary impressions following a clinician's review and approval. Additionally, it streamlines the reporting of follow-up thyroid studies. New medical AI centre launched in Victoria A new centre for innovations in medical AI has been established at La Trobe University in Victoria. Backed by A$10 million ($6.8 million) in funding from the state government, the Australian Centre for Artificial Intelligence in Medical Innovation aims to develop AI to discover new treatments, vaccines, and immunotherapies for cancers, diseases, and viruses. An AI-powered colour map for tracking and predicting breast cancer spread and a biosensor for cancer cell detection are among projects in the pipeline. A media release also noted that the centre will be the first to access Nvidia's supercomputer DGXH200 in Australia. National healthcare AI implementation guide sought in NZ New Zealand general practices seek official national guidance on AI implementation and use in healthcare, a recent survey noted. A group of primary care organisations, AI in Primary Care, surveyed GPs over the past two months to inquire about how AI is being used in primary care in the country. It was revealed that about a quarter of around 300 respondents are using AI daily in their work. Meanwhile, according to Dr Janine Bycroft, founder and CEO of Health Navigator Charitable Trust, the survey findings also point to organisations seeking "some sort of endorsement or framework from our national authorities that could be a game changer in terms of trust and acceptance for people." Currently, a comprehensive AI implementation guide by the WellSouth Primary Health Network is available to GPs in the country. Holding webinars and conducting privacy impact assessments are other ways primary care organisations have been promoting AI adoption within the sector.

BioNTech will break ground on a clinical-stage manufacturing site in Melbourne, Australia, next year. The move part of the drugmaker's effort to build bridges around the world, furthering its ambitions in creating innovative mRNA products. BioNTech has firmed up its plans in Australia, signing a multi-year partnership with the state of Victoria to research, develop and manufacture new mRNA medicines, with the goal of treating up to 4,000 cancer patients—in clinical trials or with authorized therapies—over a ten-year period in the region. BioNTech will build its research and clinical-stage manufacturing site at LaTrobe University’s Melbourne campus, breaking ground next year. At the site, the drugmaker will employ its mobile, digitally enabled modular manufacturing units, BioNTainers. One will manufacture mRNA and formulated drugs. A second unit will handle fill-finish, the company said. During a press event Friday morning at the planned site, government officials also announced that Victoria will build the Centre for AI in Medical Innovation (CAMI) next door to BioNTech’s site, which will develop artificial intelligence innovations and provide pathway opportunities for researchers and students. The agreement builds on a letter of intent the company signed with Victoria in October of 2022. “This partnership means more mRNA expertise in our state, more treatments for people with hard-to-treat cancers and 1,200 local jobs,” Victorian premier Jacinta Allan said at the press event, which included BioNTech’s chief operating officer Sierk Poetting. BioNTech also will set up an mRNA innovation center in Melbourne. The company added that it will identify mRNA-focused research projects from academia and the biotech industry and help transition them into clinical-stage development. With the success of its Pfizer-partnered COVID-19 vaccine Comirnaty, BioNTech has taken its growth ambitions worldwide. Last year, the company broke ground on a site in Kigali, Rwanda, which is due to come online next year. BioNTech also plans BioNTainer setups in South Africa and Senegal. “BioNTech’s vision is to translate science into survival,” CEO Ugur Sahin, M.D., said in a release. “The State of Victoria is one of the leading life sciences hubs in the Asia Pacific region, and we are looking forward to strengthening its cutting-edge research and development.”